Cellectar Biosciences, Inc. (CLRB) 10-Year Financial Performance & Capital Metrics

CLRB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Show more

Revenue $0
EBITDA -$51M -32.8%
Net Income -$45M -4.2%
EPS (Diluted) -41.89 +60.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17221.69%
ROIC -
Debt/Equity 0.03
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM62.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM81.02%

ROCE

10Y Avg-509.83%

5Y Avg-982.27%

3Y Avg-1913.54%

Latest-3693.99%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	362.5K	356.67K	1.55M	82.27K	189.36K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-362.5K	-356.67K	-1.55M	-82.27K	-189.36K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.02%	-3.33%	0.95%	-1.3%	1%	-	-	-	-
Operating Expenses+	8.55M	9.45M	13.6M	11.66M	13.99M	15.29M	24.13M	28.81M	38.96M	51.78M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.4M	4.7M	4.14M	4.82M	4.99M	5.15M	6.54M	9.59M	11.69M	25.64M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.16M	4.75M	9.47M	6.84M	9M	10.14M	17.59M	19.22M	27.27M	26.14M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.76M	-9.45M	-13.6M	-13.33M	-14.18M	-15.29M	-24.13M	-28.81M	-38.96M	-51.78M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.11%	-0.08%	-0.44%	0.02%	-0.06%	-0.08%	-0.58%	-0.19%	-0.35%	-0.33%
EBITDA+	-8.4M	-9.09M	-12.05M	-13.25M	-13.99M	-15.08M	-23.98M	-28.67M	-38.77M	-51.49M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.12%	-0.08%	-0.33%	-0.1%	-0.06%	-0.08%	-0.59%	-0.2%	-0.35%	-0.33%
D&A (Non-Cash Add-back)	362.5K	356.67K	1.55M	82.27K	189.36K	207.93K	149.91K	148.44K	192.38K	291.65K
EBIT	-8.55M	-9.45M	-13.6M	-13.24M	-14.09M	-15.09M	-24.13M	-28.81M	-38.96M	-51.78M
Net Interest Income+	-841	0	0	0	42.71K	10.9K	2.28K	152.52K	387.15K	1.21M
Interest Income	0	0	0	0	42.71K	10.9K	2.28K	152.52K	387.15K	1.21M
Interest Expense	841	7.9K	16.61K	29.69K	0	0	0	0	0	0
Other Income/Expense	3.26M	3.27M	38.68K	-1.58M	85.71K	196.18K	8.92K	-3.04M	-3.87M	7.26M
Pretax Income+	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.85M	-42.83M	-44.52M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	-60K	-60K	66K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.79M	-42.77M	-44.58M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.32%	-0.12%	-1.19%	0.02%	-0.06%	-0.07%	-0.6%	-0.32%	-0.35%	-0.04%
Net Income (Continuing)	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.79M	-42.77M	-44.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-21090.00	-6420.00	-3210.00	-1567.96	-550.86	-228.55	-130.35	-135.18	-104.99	-41.89
EPS Growth %	0.6%	0.7%	0.5%	0.51%	0.65%	0.59%	0.43%	-0.04%	0.22%	0.6%
EPS (Basic)	-21090.00	-6420.00	-3210.00	-1567.96	-550.86	-228.55	-130.35	-135.18	-104.99	-36.52
Diluted Shares Outstanding	261	1.46K	4.68K	9.87K	25.58K	66.04K	185.05K	235.19K	407.38K	1.24M
Basic Shares Outstanding	261	1.46K	4.68K	9.87K	25.58K	66.04K	185.05K	235.19K	407.38K	1.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.18M	12.19M	10.47M	13.95M	11.39M	57.94M	36.57M	20.53M	10.45M	24.25M
Cash & Short-Term Investments	3.86M	11.44M	10.01M	13.26M	10.61M	57.17M	35.7M	19.87M	9.56M	23.29M
Cash Only	3.86M	11.44M	10.01M	13.26M	10.61M	57.17M	35.7M	19.87M	9.56M	23.29M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	55K	55K	55K	55K	0	0	0	663.24K	888.23K	961.66K
Total Non-Current Assets+	3.42M	3.13M	1.93M	1.1M	865.14K	719.56K	630.35K	1.06M	1.62M	1.22M
Property, Plant & Equipment	1.73M	1.44M	244.71K	543.34K	783.92K	638.35K	549.13K	978.98K	1.59M	1.19M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.68M	1.68M	1.68M	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	11.87K	11.87K	11.87K	558.91K	81.21K	81.21K	81.21K	81.21K	29.78K	29.78K
Total Assets+	7.6M	15.32M	12.87M	15.05M	12.25M	58.66M	37.2M	21.59M	12.08M	25.47M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.43%	1.02%	-0.16%	0.17%	-0.19%	3.79%	-0.37%	-0.42%	-0.44%	1.11%
Total Current Liabilities+	5.7M	1.63M	2.11M	1.62M	2.77M	3.56M	3.99M	11.5M	25.36M	9.39M
Accounts Payable	0	1.42M	1.87M	1.54M	1.28M	1.43M	1.42M	2.56M	5.62M	4.11M
Days Payables Outstanding	-	1.45K	440.95	6.85K	2.46K	-	-	-	-	-
Short-Term Debt	243.59K	86.59K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	5.46M	127.13K	243.99K	76.09K	990.87K	0	1.94M	7.98M	17.61M	4.59M
Current Ratio	0.73x	7.47x	4.95x	8.60x	4.11x	16.26x	9.16x	1.78x	0.41x	2.58x
Quick Ratio	0.73x	7.47x	4.95x	8.60x	4.11x	16.26x	9.16x	1.78x	0.41x	2.58x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	243.53K	151.83K	2.21K	171K	421.64K	301.74K	166.29K	552.98K	494K	1.79M
Long-Term Debt	86.63K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	7.97K	5.25K	2.21K	0	421.64K	301.74K	166.29K	552.98K	494K	409.59K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	148.92K	146.58K	0	171K	0	0	0	0	0	1.38M
Total Liabilities	5.95M	1.78M	2.12M	1.79M	3.19M	3.86M	4.16M	12.05M	25.85M	11.18M
Total Debt+	340.65K	94.57K	5.25K	2.21K	527.53K	421.64K	301.74K	603.83K	552.98K	494K
Net Debt	-3.52M	-11.35M	-10M	-13.25M	-10.09M	-56.74M	-35.4M	-19.26M	-9.01M	-22.79M
Debt / Equity	0.21x	0.01x	0.00x	0.00x	0.06x	0.01x	0.01x	0.06x	-	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10413.63x	-1196.63x	-819.09x	-449.04x	-	-	-	-	-	-
Total Equity+	1.65M	13.54M	10.75M	13.26M	9.06M	54.79M	33.05M	9.54M	-13.78M	14.29M
Equity Growth %	-0.85%	7.21%	-0.21%	0.23%	-0.32%	5.05%	-0.4%	-0.71%	-2.44%	2.04%
Book Value per Share	6329.37	9305.75	2299.44	1343.15	354.12	829.69	178.57	40.54	-33.82	11.55
Total Shareholders' Equity	1.65M	13.54M	10.75M	13.26M	9.06M	54.79M	33.05M	9.54M	-13.78M	14.29M
Common Stock	9	104	167	47	94	454	611	94	207	461
Retained Earnings	-64.61M	-70.79M	-84.35M	-97.59M	-111.68M	-126.78M	-150.9M	-159.99M	-202.76M	-247.34M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.21M	-8.28M	-11.02M	-11.44M	-11.69M	-13.93M	-22.57M	-25.22M	-32.38M	-47.58M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.07%	-0.01%	-0.33%	-0.04%	-0.02%	-0.19%	-0.62%	-0.12%	-0.28%	-0.47%
Net Income	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-28.6M	-42.77M	-44.58M
Depreciation & Amortization	362.5K	356.67K	1.55M	82.27K	132.8K	141.45K	149.91K	148.44K	192.38K	291.65K
Stock-Based Compensation	447.3K	529.16K	758.76K	721.21K	866.79K	467.54K	1.12M	1.45M	2.41M	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-3.26M	-3.26M	-22.07K	1.56M	13.56K	-118.8K	80.66K	93.82K	4.32M	-1.57M
Working Capital Changes	-265.52K	273.81K	259.26K	-569.05K	1.39M	671.24K	198.76K	1.68M	3.48M	-1.73M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	-1.59M
Cash from Investing+	-58.47K	-72.25K	-346.7K	-329.99K	-24.54K	-62.35K	-141.36K	-225.97K	-864.04K	-104.19K
Capital Expenditures	-58.47K	-72.25K	-346.7K	-384.99K	-24.54K	-62.35K	-141.36K	-225.97K	-864.04K	-104.19K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	55K	0	0	0	0	0	0
Cash from Financing+	2.71M	15.94M	9.93M	15.02M	9.02M	60.55M	1.25M	9.61M	22.94M	61.41M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-470.73K	363.78K	2.85M	-762	0	642.5K	1.21M	-9.61M	789.64K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.27M	-8.35M	-11.37M	-11.83M	-11.72M	-14M	-22.71M	-25.45M	-33.24M	-47.69M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.07%	-0.01%	-0.36%	-0.04%	0.01%	-0.19%	-0.62%	-0.12%	-0.31%	-0.43%
FCF per Share	-31732.92	-5741.90	-2430.40	-1197.92	-458.05	-211.91	-122.72	-108.20	-81.60	-38.52
FCF Conversion (FCF/Net Income)	1.49x	1.34x	0.81x	0.86x	0.83x	0.92x	0.94x	0.79x	0.76x	1.07x
Interest Paid	45.54K	4.35K	364	0	880	1.58K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-88.66%	-81.38%	-111.65%	-110.25%	-126.28%	-47.28%	-54.92%	-149.33%	-	-17221.69%
Return on Invested Capital (ROIC)	-	-4395.53%	-693.19%	-2628.14%	-	-	-	-	-	-
Debt / Equity	0.21x	0.01x	0.00x	0.00x	0.06x	0.01x	0.01x	0.06x	-	0.03x
Interest Coverage	-10413.63x	-1196.63x	-819.09x	-449.04x	-	-	-	-	-	-
FCF Conversion	1.49x	1.34x	0.81x	0.86x	0.83x	0.92x	0.94x	0.79x	0.76x	1.07x

Frequently Asked Questions

Growth & Financials

Cellectar Biosciences, Inc. (CLRB) grew revenue by 0.0% over the past year. Growth has been modest.

Cellectar Biosciences, Inc. (CLRB) reported a net loss of $18.9M for fiscal year 2024.

Dividend & Returns

Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -17221.7%. Negative ROE indicates the company is unprofitable.

Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $29.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cellectar Biosciences, Inc. (CLRB) 10-Year Financial Performance & Capital Metrics

CLRB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0
EBITDA -$51M -32.8%
Net Income -$45M -4.2%
EPS (Diluted) -41.89 +60.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17221.69%
ROIC -
Debt/Equity 0.03
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM62.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM81.02%

ROCE

10Y Avg-509.83%

5Y Avg-982.27%

3Y Avg-1913.54%

Latest-3693.99%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	362.5K	356.67K	1.55M	82.27K	189.36K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-362.5K	-356.67K	-1.55M	-82.27K	-189.36K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.02%	-3.33%	0.95%	-1.3%	1%	-	-	-	-
Operating Expenses+	8.55M	9.45M	13.6M	11.66M	13.99M	15.29M	24.13M	28.81M	38.96M	51.78M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.4M	4.7M	4.14M	4.82M	4.99M	5.15M	6.54M	9.59M	11.69M	25.64M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.16M	4.75M	9.47M	6.84M	9M	10.14M	17.59M	19.22M	27.27M	26.14M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.76M	-9.45M	-13.6M	-13.33M	-14.18M	-15.29M	-24.13M	-28.81M	-38.96M	-51.78M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.11%	-0.08%	-0.44%	0.02%	-0.06%	-0.08%	-0.58%	-0.19%	-0.35%	-0.33%
EBITDA+	-8.4M	-9.09M	-12.05M	-13.25M	-13.99M	-15.08M	-23.98M	-28.67M	-38.77M	-51.49M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.12%	-0.08%	-0.33%	-0.1%	-0.06%	-0.08%	-0.59%	-0.2%	-0.35%	-0.33%
D&A (Non-Cash Add-back)	362.5K	356.67K	1.55M	82.27K	189.36K	207.93K	149.91K	148.44K	192.38K	291.65K
EBIT	-8.55M	-9.45M	-13.6M	-13.24M	-14.09M	-15.09M	-24.13M	-28.81M	-38.96M	-51.78M
Net Interest Income+	-841	0	0	0	42.71K	10.9K	2.28K	152.52K	387.15K	1.21M
Interest Income	0	0	0	0	42.71K	10.9K	2.28K	152.52K	387.15K	1.21M
Interest Expense	841	7.9K	16.61K	29.69K	0	0	0	0	0	0
Other Income/Expense	3.26M	3.27M	38.68K	-1.58M	85.71K	196.18K	8.92K	-3.04M	-3.87M	7.26M
Pretax Income+	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.85M	-42.83M	-44.52M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	-60K	-60K	66K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.79M	-42.77M	-44.58M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.32%	-0.12%	-1.19%	0.02%	-0.06%	-0.07%	-0.6%	-0.32%	-0.35%	-0.04%
Net Income (Continuing)	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-31.79M	-42.77M	-44.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-21090.00	-6420.00	-3210.00	-1567.96	-550.86	-228.55	-130.35	-135.18	-104.99	-41.89
EPS Growth %	0.6%	0.7%	0.5%	0.51%	0.65%	0.59%	0.43%	-0.04%	0.22%	0.6%
EPS (Basic)	-21090.00	-6420.00	-3210.00	-1567.96	-550.86	-228.55	-130.35	-135.18	-104.99	-36.52
Diluted Shares Outstanding	261	1.46K	4.68K	9.87K	25.58K	66.04K	185.05K	235.19K	407.38K	1.24M
Basic Shares Outstanding	261	1.46K	4.68K	9.87K	25.58K	66.04K	185.05K	235.19K	407.38K	1.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.18M	12.19M	10.47M	13.95M	11.39M	57.94M	36.57M	20.53M	10.45M	24.25M
Cash & Short-Term Investments	3.86M	11.44M	10.01M	13.26M	10.61M	57.17M	35.7M	19.87M	9.56M	23.29M
Cash Only	3.86M	11.44M	10.01M	13.26M	10.61M	57.17M	35.7M	19.87M	9.56M	23.29M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	55K	55K	55K	55K	0	0	0	663.24K	888.23K	961.66K
Total Non-Current Assets+	3.42M	3.13M	1.93M	1.1M	865.14K	719.56K	630.35K	1.06M	1.62M	1.22M
Property, Plant & Equipment	1.73M	1.44M	244.71K	543.34K	783.92K	638.35K	549.13K	978.98K	1.59M	1.19M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.68M	1.68M	1.68M	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	11.87K	11.87K	11.87K	558.91K	81.21K	81.21K	81.21K	81.21K	29.78K	29.78K
Total Assets+	7.6M	15.32M	12.87M	15.05M	12.25M	58.66M	37.2M	21.59M	12.08M	25.47M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.43%	1.02%	-0.16%	0.17%	-0.19%	3.79%	-0.37%	-0.42%	-0.44%	1.11%
Total Current Liabilities+	5.7M	1.63M	2.11M	1.62M	2.77M	3.56M	3.99M	11.5M	25.36M	9.39M
Accounts Payable	0	1.42M	1.87M	1.54M	1.28M	1.43M	1.42M	2.56M	5.62M	4.11M
Days Payables Outstanding	-	1.45K	440.95	6.85K	2.46K	-	-	-	-	-
Short-Term Debt	243.59K	86.59K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	5.46M	127.13K	243.99K	76.09K	990.87K	0	1.94M	7.98M	17.61M	4.59M
Current Ratio	0.73x	7.47x	4.95x	8.60x	4.11x	16.26x	9.16x	1.78x	0.41x	2.58x
Quick Ratio	0.73x	7.47x	4.95x	8.60x	4.11x	16.26x	9.16x	1.78x	0.41x	2.58x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	243.53K	151.83K	2.21K	171K	421.64K	301.74K	166.29K	552.98K	494K	1.79M
Long-Term Debt	86.63K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	7.97K	5.25K	2.21K	0	421.64K	301.74K	166.29K	552.98K	494K	409.59K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	148.92K	146.58K	0	171K	0	0	0	0	0	1.38M
Total Liabilities	5.95M	1.78M	2.12M	1.79M	3.19M	3.86M	4.16M	12.05M	25.85M	11.18M
Total Debt+	340.65K	94.57K	5.25K	2.21K	527.53K	421.64K	301.74K	603.83K	552.98K	494K
Net Debt	-3.52M	-11.35M	-10M	-13.25M	-10.09M	-56.74M	-35.4M	-19.26M	-9.01M	-22.79M
Debt / Equity	0.21x	0.01x	0.00x	0.00x	0.06x	0.01x	0.01x	0.06x	-	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10413.63x	-1196.63x	-819.09x	-449.04x	-	-	-	-	-	-
Total Equity+	1.65M	13.54M	10.75M	13.26M	9.06M	54.79M	33.05M	9.54M	-13.78M	14.29M
Equity Growth %	-0.85%	7.21%	-0.21%	0.23%	-0.32%	5.05%	-0.4%	-0.71%	-2.44%	2.04%
Book Value per Share	6329.37	9305.75	2299.44	1343.15	354.12	829.69	178.57	40.54	-33.82	11.55
Total Shareholders' Equity	1.65M	13.54M	10.75M	13.26M	9.06M	54.79M	33.05M	9.54M	-13.78M	14.29M
Common Stock	9	104	167	47	94	454	611	94	207	461
Retained Earnings	-64.61M	-70.79M	-84.35M	-97.59M	-111.68M	-126.78M	-150.9M	-159.99M	-202.76M	-247.34M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.21M	-8.28M	-11.02M	-11.44M	-11.69M	-13.93M	-22.57M	-25.22M	-32.38M	-47.58M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.07%	-0.01%	-0.33%	-0.04%	-0.02%	-0.19%	-0.62%	-0.12%	-0.28%	-0.47%
Net Income	-5.5M	-6.18M	-13.56M	-13.24M	-14.09M	-15.09M	-24.12M	-28.6M	-42.77M	-44.58M
Depreciation & Amortization	362.5K	356.67K	1.55M	82.27K	132.8K	141.45K	149.91K	148.44K	192.38K	291.65K
Stock-Based Compensation	447.3K	529.16K	758.76K	721.21K	866.79K	467.54K	1.12M	1.45M	2.41M	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-3.26M	-3.26M	-22.07K	1.56M	13.56K	-118.8K	80.66K	93.82K	4.32M	-1.57M
Working Capital Changes	-265.52K	273.81K	259.26K	-569.05K	1.39M	671.24K	198.76K	1.68M	3.48M	-1.73M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	-1.59M
Cash from Investing+	-58.47K	-72.25K	-346.7K	-329.99K	-24.54K	-62.35K	-141.36K	-225.97K	-864.04K	-104.19K
Capital Expenditures	-58.47K	-72.25K	-346.7K	-384.99K	-24.54K	-62.35K	-141.36K	-225.97K	-864.04K	-104.19K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	55K	0	0	0	0	0	0
Cash from Financing+	2.71M	15.94M	9.93M	15.02M	9.02M	60.55M	1.25M	9.61M	22.94M	61.41M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-470.73K	363.78K	2.85M	-762	0	642.5K	1.21M	-9.61M	789.64K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.27M	-8.35M	-11.37M	-11.83M	-11.72M	-14M	-22.71M	-25.45M	-33.24M	-47.69M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.07%	-0.01%	-0.36%	-0.04%	0.01%	-0.19%	-0.62%	-0.12%	-0.31%	-0.43%
FCF per Share	-31732.92	-5741.90	-2430.40	-1197.92	-458.05	-211.91	-122.72	-108.20	-81.60	-38.52
FCF Conversion (FCF/Net Income)	1.49x	1.34x	0.81x	0.86x	0.83x	0.92x	0.94x	0.79x	0.76x	1.07x
Interest Paid	45.54K	4.35K	364	0	880	1.58K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-88.66%	-81.38%	-111.65%	-110.25%	-126.28%	-47.28%	-54.92%	-149.33%	-	-17221.69%
Return on Invested Capital (ROIC)	-	-4395.53%	-693.19%	-2628.14%	-	-	-	-	-	-
Debt / Equity	0.21x	0.01x	0.00x	0.00x	0.06x	0.01x	0.01x	0.06x	-	0.03x
Interest Coverage	-10413.63x	-1196.63x	-819.09x	-449.04x	-	-	-	-	-	-
FCF Conversion	1.49x	1.34x	0.81x	0.86x	0.83x	0.92x	0.94x	0.79x	0.76x	1.07x

Frequently Asked Questions

Growth & Financials

Cellectar Biosciences, Inc. (CLRB) grew revenue by 0.0% over the past year. Growth has been modest.

Cellectar Biosciences, Inc. (CLRB) reported a net loss of $18.9M for fiscal year 2024.

Dividend & Returns

Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -17221.7%. Negative ROE indicates the company is unprofitable.

Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $29.7M in fiscal year 2024, likely due to heavy capital investments.